BRIEF-Seelos Therapeutics Announces Acquisition of an Exclusive License of iX Biopharma's Proprietary Wafer-Based Delivery Platform for Sublingual Ketamine
BRIEF-Seelos Therapeutics Announces Acquisition of an Exclusive License of iX Biopharma's Proprietary Wafer-Based Delivery Platform for Sublingual Ketamine
Nov 24 (Reuters) - Seelos Therapeutics Inc SEEL.O :
路透11月24日電-Seelos治療公司SEEL.O：
* SEELOS THERAPEUTICS ANNOUNCES ACQUISITION OF AN EXCLUSIVE LICENSE OF IX BIOPHARMA'S PROPRIETARY WAFER-BASED DELIVERY PLATFORM FOR SUBLINGUAL KETAMINE
*SEELOS治療公司宣佈收購IX BioPharma公司基於晶片的舌下氯胺酮專有遞送平臺的獨家許可證
* SEELOS THERAPEUTICS INC - NEW SLS-003 PROGRAM EXTENDS SEELOS' KETAMINE FRANCHISE INTO ADDITIONAL INDICATIONS INCLUDING CHRONIC NEUROPATHIC PAIN
*SEELOS治療公司-新的SLS-003計劃將SEELOS的氯胺酮專營權擴大到其他適應症，包括慢性神經性疼痛
* SEELOS THERAPEUTICS INC - SEELOS PLANS TO EVALUATE SUBLINGUAL KETAMINE, NOW NAMED SLS-003, IN PAIN INDICATIONS
*SEELOS治療公司-SEELOS計劃評估舌下氯胺酮，現在命名為SLS-003，用於疼痛適應症
* SEELOS THERAPEUTICS INC - PURSUANT TO LICENSE AGREEMENT, SEELOS WILL PAY IX BIOPHARMA A ONE-TIME, UPFRONT FEE OF $9 MILLION
*SEELOS治療公司-根據許可協議，SEELOS將向IX BioPharma A一次性支付900萬美元的預付費用
Source text for Eikon: ID:nPn7sB5Xna Further company coverage: SEEL.O
Eikon的源文本：ID：nPn7sB5Xna進一步的公司報道：SEEL.O
((Reuters.Briefs@thomsonreuters.com;;))
(Reurs.Briefs@thomsonreurs.com；；)
譯文內容由第三人軟體翻譯。